Overgaard K
Department of Neurology, University Hospital of Copenhagen, Rigshospitalet, Denmark.
Cerebrovasc Brain Metab Rev. 1994 Fall;6(3):257-86.
The effect of thrombolytic therapy is well-documented in acute myocardial infarction. In acute cerebral infarction, thrombolytic therapy has been evaluated in small series of patients. The point of thrombolytic therapy is to avoid or reduce ischemic damage of neuronal tissue by rapid arterial recanalization. In thrombolytic therapy of cerebral vascular occlusion, the pathophysiology of reperfusion needs further investigation and documentation. This review describes studies of thrombolysis in embolic stroke using animals embolized by intracarotid injections of blood clots. Vascular occlusion was demonstrated by angiography and measurement of cerebral blood flow. Thrombolytic therapy with recombinant tissue-type plasminogen activator was initiated after varying periods of time. Reperfusion, cellular function, and brain damage were examined by angiography and by clinical and pathoanatomical examination. Based mainly on results from our own investigations, the following theses concerning ischemic stroke were made: (a) Cerebral infarction caused by arterial occlusion is due to delayed, incomplete, or no reperfusion. Spasms, or hemodynamic mechanisms, seem to be of only minor importance. (b) Early thrombolytic therapy in animal models increases the degree of reperfusion and reduces brain damage, clinical deficits, and mortality. (c) Early arterial reperfusion reduces cerebral infarction and related edema. With early reperfusion, the extent of brain damage correlates to the length of the delay from onset of ischemia. (d) Cerebral stunning is caused by arterial occlusion followed by very early spontaneous or induced reperfusion, as neurons temporarily lose their functional capabilities without dying. (e) Multiple embolic microclots in experimental stroke result in more brain damage than a single macroclot, and with clots the extent of brain damage is dependent on the structural composition and volume of emboli. (f) The ability to recanalization in experimental embolic stroke is related to the amount of red cells in the emboli and inversely related to the volume of emboli and to the fibrin content and density of the clots. (g) Infarct-limiting effects in experimental stroke can be obtained by ischemic neuroprotectants or by hypothermia, either alone or with thrombolytic therapy, which then reduces brain damage further.
溶栓疗法在急性心肌梗死中的效果已有充分记录。在急性脑梗死中,溶栓疗法已在少数患者系列中进行了评估。溶栓疗法的关键在于通过快速动脉再通来避免或减少神经元组织的缺血性损伤。在脑血管闭塞的溶栓治疗中,再灌注的病理生理学需要进一步研究和记录。本综述描述了使用经颈内动脉注射血凝块栓塞的动物进行栓塞性中风溶栓研究。通过血管造影和脑血流量测量来证实血管闭塞。在不同时间段后开始用重组组织型纤溶酶原激活剂进行溶栓治疗。通过血管造影以及临床和病理解剖检查来检查再灌注、细胞功能和脑损伤。主要基于我们自己的研究结果,得出了以下关于缺血性中风的论点:(a) 动脉闭塞引起的脑梗死是由于再灌注延迟、不完全或无再灌注。痉挛或血流动力学机制似乎仅起次要作用。(b) 动物模型中的早期溶栓治疗可增加再灌注程度并减少脑损伤、临床缺陷和死亡率。(c) 早期动脉再灌注可减少脑梗死和相关水肿。早期再灌注时,脑损伤程度与缺血发作后延迟时间的长短相关。(d) 脑震荡是由动脉闭塞后非常早期的自发或诱导再灌注引起的,因为神经元暂时失去其功能能力但未死亡。(e) 实验性中风中的多个栓塞微血栓比单个大血栓导致更多的脑损伤,并且对于血栓,脑损伤程度取决于栓子的结构组成和体积。(f) 实验性栓塞性中风中的再通能力与栓子中的红细胞数量有关,与栓子体积、血栓的纤维蛋白含量和密度成反比。(g) 在实验性中风中,缺血性神经保护剂或低温单独或与溶栓疗法联合使用可获得梗死限制效果,从而进一步减少脑损伤。